DCM II TRIAL (NCT04476901) 

A Phase IIB, randomized, placebo-controlled, multicenter study of the comparative efficacy and safety of administration of allogeneic mesenchymal stem cells versus placebo in patients with non-ischemic dilated cardiomyopathy.

PI: Emerson Perin, MD, PhD

SPONSOR: University of Miami

ACTIVE ENROLLING   SIGN UP

The Texas Heart Institute Center for Clinical Research is conducting a phase IIB, randomized, double-blinded, placebo-controlled trial that will evaluate the safety and effectiveness of administered human allogeneic mesenchymal stem cells (hMSCs) compared to placebo in patients with Non-Ischemic Dilated Cardiomyopathy (DCM).  Patients will be followed at regular intervals over a one-year period to evaluate changes in cardiac function & quality of life.

Eligibility Requirements

• Males and females, between 18-80 years of age.
• Diagnosis of Non-Ischemic Dilated Cardiomyopathy
• Ejection Fraction of < 45%
• Willing to undergo DNA Test

DCM II Patient Brochure